PDSBライブシグナル | Getagraph.comで利益を最大化

売る 107960 min ago

@ $5.26

発行日: 15 2月 2024 @ 02:24

リターン: -36.12%

前回のシグナル: 2月 13 - 02:29

前回のシグナル: 買う

リターン: -3.66 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:44):

Stats
本日の出来高	239 920
平均出来高	909 772
時価総額	123.24M
EPS	$0 ( 2024-03-27 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.42
ATR14	$0.00800 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Shepard Kirk V.	Buy	200 000	Employee Stock Option (Right to Buy)
2024-01-22	Shepard Kirk V.	Buy	0
2023-12-04	Boesgaard Lars	Buy	200 000	Employee Stock Option (Right to Buy)
2023-12-04	Boesgaard Lars	Buy	0
2023-07-14	Freitag Gregory Gene	Buy	9 000	Employee Stock Option (Right to Buy)

INSIDER POWER
71.59
Last 91 transactions
Buy: 4 791 106 \| Sell: 920 084

ボリューム相関

長: 0.23 (neutral)

短: -0.92 (very strong negative)

Signal:(31.424) Neutral

PDS Biotechnology Corp 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

PDS Biotechnology Corp 相関 - 通貨/商品

0.27
( neutral )

0.38
( neutral )

0.00
( neutral )

0.78
( moderate )

-0.51
( weak negative )

-0.82
( strong negative )

PDS Biotechnology Corp 財務諸表

Annual	2023
収益:	$0
総利益:	$-57 326.00 (0.00 %)
EPS:	$-1.390

FY	2023
収益:	$0
総利益:	$-57 326.00 (0.00 %)
EPS:	$-1.390

FY	2022
収益:	$0
総利益:	$-49 078.00 (0.00 %)
EPS:	$-1.430

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.660

Financial Reports:

No articles found.

PDS Biotechnology Corp

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.